P33 | IMPACT OF CYCLIN C EXPRESSION ON THE AGGRESSIVENESS OF A549 NON-SMALL CELL LUNG CANCER CELLS
V. Havryliuk | Department of Histology and Embryology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Non-small cell lung cancer (NSCLC), accounting for the majority of lung cancer cases, is a malignancy with complex molecular background and high treatment resistance, complicating effective therapy. Identifying new molecular therapeutic targets remains a significant research challenge. Cyclin C (CCNC) is a cell cycle regulatory protein that, in complex with CDK3, controls the transition from G0 to G1 phase, and together with CDK8/CDK19 participates in gene transcription regulation. Depending on cancer type, Cyclin C may act as both tumor suppressor and oncogene. Its role in NSCLC remains poorly understood. This study aimed to assess the impact of Cyclin C expression on the aggressiveness of A549 cells. shRNA-mediated transduction was used to downregulate CCNC expression. Verification of knockdown efficacy by immunofluorescence and western blot revealed significant phenotypic changes. Cyclin C silencing in A549 cells causes proliferation arrest by prolonging the cell cycle in the G2/M phase. Reduced Cyclin C expression leads to decreased cell viability, suggesting an important role of Cyclin C in maintaining proliferation and survival of cancer cells.
Downloads
Citations
Supporting Agencies
-Data Availability Statement
OAHow to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
